Vyant Bio announces the appointment of a new board of directors
CHERRY HILL, NJ, April 5, 2021 (GLOBE NEWSWIRE) – Vyant Bio, Inc. (the “Company”) (Nasdaq: VYNT), is a new force in drug discovery, focused on integrating human-powered science and technology systems to reduce risk and accelerate the discovery of therapies for biopharmaceutical partners as well. only for the Company’s exclusive pipeline. Its newly formed Board of Directors is drawn from the disciplines of Drug Discovery and Development, Pharmaceuticals, and Life Sciences Strategy and Finance. The new board members bring decades of experience and leadership to help guide the company on its path to discovering innovative and market-leading drugs.
The company is led in the executive suite by Jay Roberts, Managing Director, Ping Yeh, Chief Innovation Officer and Andy LaFrence, Chief Financial Officer. Join MM. Roberts and Yeh on the new board are:
John Fletcher, our Chairman of the Board, bringing to the Board over 30 years of strategic and financing experience in the pharmaceutical and healthcare industries. He is the Founder and CEO of Fletcher Spaght, Inc., a consulting firm that provides growth-oriented strategic assistance to corporate clients. Since 2001, Mr. Fletcher has also been Managing Partner of Fletcher Spaght Ventures, a venture capital fund. Mr. Fletcher is the Chairman of the Board of Directors of Vyant Bio.
Joanna Horobin MB, Ch.B., an accomplished drug developer and biotechnology leader with over 35 years of experience in the pharmaceutical and biotechnology industry. Dr Horobin is currently Chairman of the Board of Directors of iOnctura SA, a private oncology company and non-executive director of the Boards of Kymera Therapeutics, Inc. (NASDAQ: KYMR), Nordic Nanovector ASA (Oslo: NANO ) and Liquidia Technologies, Inc. (NASDAQ: LQDA). Dr Horobin has held a number of senior positions in biotechnology companies in the United States, most recently as Medical Director of Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) and also served as Managing Director of Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX).
Marcus F. Boehm, Ph.D. co-founded and is currently Scientific Director of Escient Pharmaceuticals, Inc. Previously, he was co-founder of Receptos, Inc. where he served as CTO until its acquisition by Celgene Corporation. In 2001, Dr. Boehm was a founding member of Conforma Therapeutics Corporation, which was acquired by Biogen Idec. Dr Boehm began his career in industry with Ligand Pharmaceuticals in 1991, where he held various positions with increasing responsibilities.
Geoffroy harris is the Managing Partner of c7 Advisors (a financial management and healthcare consulting firm). Previously, he was Managing Director and Co-Head of Healthcare Investment Banking Group at Cantor Fitzgerald, and a similar position at Gleacher & Company. Mr. Harris is also currently a member of the board of directors of Telemynd, Inc. (formerly MYnd Analytics); PointRight Inc. and MoleSafe, Inc.
Howard McLeod, Pharm.D. is the Medical Director of Precision Medicine for the Geriatric Oncology Consortium and a professor at USF Taneja College of Pharmacy. Previously, he was Chairman of the Department of Individualized Cancer Management and Medical Director of the DeBartolo Family Personalized Medicine Institute at the Moffitt Cancer Center and previously a Senior Fellow of the Division of Population Sciences at the Moffitt Cancer Center. He also chaired the Department of Individualized Cancer Management at Moffitt. Prior to joining the Moffitt Cancer Center, Dr. McLeod was the founding director of the Institute of Pharmacogenomics and Individualized Therapy at the University of North Carolina. Dr McLeod also held the prestigious title of Fred Eshelman Distinguished Professor at the UNC Eshelman School of Pharmacy.
Paul hansen has been a member of the StemoniX Board of Directors since 2015. Since 2014, Mr. Hansen has been a Senior Fellow at the Technological Leadership Institute at the University of Minnesota. Mr. Hansen is Founder and President of Minnepura Technologies, SBC. Mr. Hansen has also held senior management positions at 3M Company, including President and CEO of 3M Mexico.
“Each of the individuals selected to join our Board of Directors is highly qualified and brings a unique perspective based on years of experience in innovating and creating tremendous shareholder value. The breadth and depth of knowledge of the Board of Directors will be an invaluable asset as Vyant Bio embarks on a new era in drug discovery, ”said Jay Roberts, CEO of Vyant Bio.
“I am happy that we were able to attract each of our new directors. At this point in Vyant Bio’s growth, the distinctive attributes of each of these new board members will provide direction and leadership to guide the company in its next stage of growth and to achieve its goals, ”said Ping. Yeh, innovation director of Vyant Bio. .
As a reminder, Jay Roberts, Ping Yeh and Andy LaFrence will host an investor conference call tomorrow, April 6, 2021. Please also visit the Investors section of the Vyant Bio website for more details on how to participate.
Event: Investor Webcast – Vyant Bio Announcement
Dated: Tuesday April 6, 2021
Time: 4:30 p.m. ET
Compose: (844) 954-2324 Conference number: 9757240
A live and archived webcast of the conference call will also be available in the Investors section of Vyant Bio’s website at www.vyantbio.com.
ABOUT VYANT BIO, INC.
Vyant Bio operates two wholly owned subsidiaries, StemoniX and livelyPharmacy. The Company will immediately begin executing the integration of these two leading companies, in order to converge human-powered scientific and technological systems and expertise with years of preclinical experience to reduce risk and accelerate discovery and development. preclinical and clinical pipelines for biopharmacy. partners as well as for the Company’s exclusive pipeline.
StemoniX enables the discovery of new drugs through the convergence of new human biology technologies and software. StemoniX develops and manufactures neuronal and cardiac screening platforms derived from high-density, large-scale human-induced pluripotent stem cells (iPS) for drug discovery and development. Predictive, accurate and consistent, these human models allow scientists to conduct research quickly and economically with improved results in a simplified workflow. Through collaborations with drug discovery organizations, StemoniX tests compounds in-house, creates new cell-based disease models, and operationalizes customized human disease models derived from iPSC for high-throughput screening at scale. . Using cutting-edge iPSC technologies and data science, StemoniX helps global institutions bring the most promising drugs to patients.
livelyPharm offers proprietary preclinical test systems supporting early stage clinical diagnostic offerings valued by the pharmaceutical industry, biotechnology companies and academic research centers. livelyPharm focuses on precision and translational medicine to drive drug discovery and new therapies. livelyPharm specializes in conducting bespoke studies to guide drug development, starting with libraries of compounds and ending with a full set of in vitro and in vivo data and reports as needed for new drug research records. livelyPharm operates in facilities accredited and GLP compliant by the Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC).
For more information, please visit or follow Vyant Bio at:
The Internet: www.vyantbio.com
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements relating to the expectations of Vyant Bio, Inc. (formerly Cancer Genetics, Inc.) regarding future financial and / or operational results , and the potential of our services, future income or growth, in this press release constitute forward-looking statements.
All statements which are not historical facts (including, but not limited to, statements which contain words such as “will”, “believes”, “plans”, “anticipates”, “expects” “And” estimates “) should also be taken into account to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, the risks inherent in our attempts to adapt to the global coronavirus pandemic, achieve profitability and increase sales of our preclinical services. , maintain our existing customer base and avoid cancellation of customer contracts or interruption of trials, raise capital to meet our liquidity needs, realize the expected benefits of the merger with StemoniX, Inc., and of other risks discussed in Vyant Bio, Inc.’s Form 10-K for the fiscal year ended December 31, 2020, as well as other documents filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Vyant Bio disclaims any obligation to update these forward-looking statements.
Jennifer K. Zimmons. doctorate
Zimmons International Communications, Inc.
E-mail: [email protected]
Source: Vyant Bio, Inc.